United States Providers

Harvard Business Review

Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength

CNBC Business

10/29/2026, 11:08:18 AM

Share:WhatsApp Facebook X (Twitter)Telegram

EXECUTIVE SUMMARY

Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.

Key Takeaways

Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength.
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.

Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.

Share:WhatsApp Facebook X (Twitter)Telegram

Read Complete Original Article

Published originally on CNBC Business

Visit Publisher Site →

Related News

🇺🇸 United States

Economy & Business1h ago

Why Are The Pacers Dealing With So Many Hamstring Injuries Already?

The Indiana Pacers are dealing with several hamstring injuries already this season. Why have they been hit by so many?

Forbes Business

Economy & Business1h ago

Julio Vaqueiro And Noticias Telemundo Will Cover Midterms With Emphasis On Latino Voters

The Spanish-language news network will provide multi-platform election coverage from Miami, debuting a high-tech new set and a focus on Latino voters, who could swing key races.

Forbes Business